TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07282574: A Multi-center, Double-blind, Placebo-controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, a Monoacylglycerol Lipase Inhibitor, as Add-on Therapy to Ocrelizumab

Sponsor: Hoffmann-La Roche · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 360 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$465,600

Rescue Site Savings

+$310,400

Unlock Full NCT07282574 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07282574 Rescue Dossier →